[Adjuvant chemotherapy of non-seminoma stage I germ cell tumors of the testis].
OBJECTIVE
To review the treatment of stage I nonseminomatous germ cell testicular tumor with adjuvant chemotherapy.


METHODS
The literature on this subject was reviewed.


CONCLUSIONS
Overall, 30% of stage I nonseminomatous germ cell testicular tumors that are followed recur within two subsequent years. Several factors associated with a higher risk have been described. The most important are the presence of venous or lymphatic infiltration, the presence of a carcinoembryonic component and the absence of tumor of the endodermal sinus. Patients with the foregoing characteristics have a recurrence rate of approximately 50%. Over the last few years, some experience using two cycles of BEP adjuvant chemotherapy in patients at a higher risk have shown that this recurrence rate can be reduced to less than 5% with minimal late toxicity.
Fernández-Ortega
A
A
Servicio de Oncología Médica, Institut Català d'Oncologia, Barcelona, España.
García del Muro
X
X
Navarro
M
M
Germà Lluch
J R
JR
D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D018237:Germinoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009367:Neoplasm Staging; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology